Wire · opportunities
Time to rethink clinical trial design in Sjögren disease
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
Clinical trial designs in Sjögren disease have shifted to focus on stratified patient populations and more precise outcome measures, enabling the development of targeted therapeutic trials that could include more patients across the disease spectrum.
This Wire brief sits within Fusion42's coverage of Biotech, Drug Discovery and Diagnostics.
◆ ◆ The Wire takeaway
You can now design clinical trials for Sjögren disease that target patient subgroups more precisely, opening therapeutic opportunities beyond broad enrolment approaches. This means your next drug trial can be more cost-effective and inclusive, gaining access to previously excluded patients.
◆ Coverage
1 source · 2 Sep 2026
◆ Related on Wire
◆ Topics